Ruth Salmon

Ruth Salmon is Vice President, Preclinical Sciences at Bristol Myers Squibb, where she leads preclinical development efforts for cell therapy and immuno-oncology candidates from post-discovery through IND-enabling stages, contributing to scientific strategy and operational leadership. She has over 18 years of experience in biotech and pharma across inflammation, oncology, and diverse therapeutic modalities, including advancing CAR-T and engineered TCR programs targeting myeloma, B-cell malignancies, and solid tumors. Ruth’s earlier work includes biologics development for autoimmunity and inflammation at Novo Nordisk, VLST Corporation, and QLT Inc. Her scientific training was focused on immunology with doctoral and post-doctoral research.